| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Legal & Adm. Officer
1 company
Caryn Gordon McDowell last filed a Form 4 in June 2022, as Chief Legal & Adm. Officer at QNCX. Caryn Gordon McDowell's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 122,500 shares of QNCX. The QNCX filings lean toward selling, a net 10,800 shares.
Caryn Gordon McDowell has 5 Form 4 filings on record from May 2020 to June 2022, all as Chief Legal & Adm. Officer at Quince Therapeutics (QNCX), 2020–2022.
The 7 reported transactions were 4 option or other derivative awards, 1 tax withholding, 1 open-market sale and 1 stock award.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $31K.
The only open-market sale was 10,800 shares of QNCX at an average $2.86 on June 6, 2022, about $31K. Twelve months later QNCX was down 48%.
Shares as reported in the last Form 4 for each company; the most recent is from June 2022. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 6, 2022 | QNCX Quince Therapeutics, Inc. | Chief Legal & Adm. Officer | Sell | 10,800 | $2.86 | $30,922.56 | -8.1% | -43.5% | -47.9% |